- IDEXX Laboratories (NASDAQ: IDXX) launches the Catalyst Cortisol Test, the third expansion of its Catalyst platform within a year.
- The test aids in diagnosing canine Addison's disease and Cushing's syndrome with real-time cortisol concentration measurements.
- Rollout scheduled for the U.S. and Canada by July 2025, with a global expansion to over 75,000 Catalyst chemistry analyzers starting Q3 2025.
IDEXX Laboratories, Inc. (IDXX, Financial), a global leader in pet healthcare innovation, has announced the launch of its new Catalyst Cortisol Test. This marks the third expansion of the Catalyst platform in less than a year, underscoring the company's rapid innovation in the veterinary diagnostics field. The Catalyst Cortisol Test is designed to measure real-time cortisol concentrations in canine patients, aiding veterinarians in diagnosing Addison's disease and Cushing's syndrome—two critical and often challenging endocrine disorders in dogs.
The test provides a significant improvement in point-of-care diagnostic capabilities, offering accuracy comparable to IDEXX Reference Laboratories. Key features include interpretive guidance through integration with IDEXX Vetlab Station and VetConnect PLUS, and a streamlined load-and-go workflow, which can significantly enhance the efficiency of veterinary practices.
Available first in the U.S. and Canada by July 2025, the Catalyst Cortisol Test will subsequently be rolled out globally, expanding to over 75,000 Catalyst chemistry analyzers starting in the third quarter of 2025. This phased rollout strategy is designed to prioritize IDEXX's highest-value markets while gradually expanding globally.
By advancing the capabilities of the Catalyst platform, IDEXX strengthens its competitive position in the market and fulfills its "Technology for Life" promise. This initiative not only enhances diagnostic accuracy and efficiency during patient visits but also supports sustained customer loyalty and the expansion of recurring revenue streams.
